Kornimate/medical-research-clean huggingface dataset:
effectiveness of cervical stabilization exercises in individuals with temporomandibular joint disorder

Conditions: Temporomandibular Joint Disorders

Summary: it is planned to examine the effect of cervical stabilization exercises on temporomandibular joint (tmj) symptoms in individuals with tmj disorder.

individuals included in the study will be divided into 2 groups, stabilization and control groups, by block randomization method. a standard treatment program (education + home exercises) will be applied to both groups. in addition to the stabilization group, cervical stabilization exercises will be applied. individuals will be evaluated with the sociodemographic data form before the application. before and after the application, individuals were assessed for tmj pain with the numeric pain rating scale (nprs), tmj symptom severity with the fonseca anamnestic index (fai) and cervical posture, mobility and muscle performance will be evaluated with craniovertebral angle, goniometer and craniocervical flexion test.

Eligibility criteria:
inclusion criteria: * having a tmj disorder according to the tmj disorders research diagnostic criteria (rdc/tmd), * being between the ages of 18-65, exclusion criteria: * neurological diseases (such as multiple sclerosis, parkinson's disease), * metabolic and systemic diseases (such as hypothyroidism, hypercalcemia, diabetes mellitus, celiac disease), * rheumatologic diseases (such as rheumatoid arthritis, scleroderma), * history of head and spine trauma/surgery in the last 6 months, * history of malignancy and pregnant women will be excluded.

Keywords: temporomandibular joint disorders
artificial intelligence-assisted screening of malignant pigmented tumors on the ocular surface

Conditions: Orbital Neoplasms; Conjunctival Neoplasms; Eye Neoplasms

Summary: rare diseases generally refer to diseases whose prevalence rate is lower than 1 / 10 000 and the number of patients is less than 140000. rare diseases are generally faced with the dilemma of a lack of qualified doctors, difficulty in large-scale screening, and a lack of rapid and effective channels for medical treatment. studies have shown that 42% of patients say they have been misdiagnosed, and each patient with a rare disease needs to go through an average of eight doctors in seven years to see a corresponding rare disease specialist. more importantly, most rare diseases seriously affect the health and quality of life of patients. the ocular surface malignant tumor is a typical rare disease, and its incidence is less than 1 / 100000. the ocular surface not only affects the patient's appearance, but also damages the visual function, and the malignant tumor may even affect life. these uncommon malignant tumors are often hidden in the common black nevus on the eye surface, which is easy to be ignored and has great potential risks. with the improvement of people's living standards, people start to pay attention to rare diseases. in recent years, the rapid development of digital technology has also provided new opportunities for the prevention and treatment of rare diseases. our team established the database of rare ophthalmopathy in china in the early stage, which provided a solid foundation for the digitization of precious clinical data. this study intends to develop an intelligent screening system for ocular surface malignant tumors, using the mobile phone for real-world verification and scale screening, and explore it to improve the ability of doctors to diagnose and treat rare diseases. this study is expected to improve the ability to screen malignant tumors on the ocular surface and provide a novel model for the universal screening of rare diseases.


Eligibility criteria:
inclusion criteria: * dark-brown lesions on the ocular surface are found: i.e. ocular surface malignant melanoma, ocular basal cell carcinoma, conjunctival nevus, eyelid nevus, sclera pigmentation, benign eyelid keratosis exclusion criteria: * non-pigmented ocular surface tumors: pterygium, corneal dermoid tumor, meibomian gland cyst, cataract, blepharitis, etc. * the image quality does not meet the clinical requirements.

Keywords: mobile health artificaial intelligence medicine ocular surface malignant tumor
transradial-band pilot study

Conditions: Radial Artery Incision Site Closure

Summary: in the study group, the tr-band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals. in the standard of care group, the tr-band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals. the aim of the study is to reduce the time the device is in place while minimizing potential complications.


Eligibility criteria:
inclusion criteria: * age 18 years and older * have an acceptable barbeau test (i.e. type a through c) * have acceptable coagulation parameters (based on pt, inr, platelet count, and appropriate pre-procedural management of anticoagulants, see table 1) * the caliber of the left radial artery based on a pre-procedure sonographic evaluation will need to be greater than or equal to 1.6 mm. * the appropriate pre-procedural management of anticoagulants is based on the consensus guidelines established by patel et al16. * inr less than 1.5 * platelet count greater than 50,000 platelet/ul * prothrombin time less than 15 seconds exclusion criteria: * if there is an unacceptable risk of bleeding diathesis, or * if he or she is not a suitable candidate for transradial access based on a barbeau test type d or a diameter of the left radial artery less than 1.6 mm.
a study evaluating gs-9620 in treatment naive subjects with chronic hepatitis b

Conditions: Hepatitis B; HBV

Summary: dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). dose escalation or repetition will be governed by pre-specified safety and activity rules. subjects will be confined on either days 1-3 or days 1-3 and 8-10. follow-up visits are also required periodically through day 43, and potential viral load follow-up visits at weeks 3 and 6 months post last dose. study procedures involve blood draws for pharmacokinetic, pharmacodynamic, virologic, and safety assessments


Eligibility criteria:
inclusion criteria: * chronic hbv infection ≥ 6 months * hbsag ≥ 250 iu/ml * hbv treatment naïve * absence of extensive bridging fibrosis (metavir 3 or greater) or cirrhosis * creatinine clearance ≥ 70 ml/min exclusion criteria: * co-infection with hepatitis c virus (hcv), hepatitis d virus (hdv), or hiv * history of gilberts disease * laboratory parameters not within defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia, thyroid-stimulating hormone (tsh), or other evidence of hepatic decompensation * diagnosis of autoimmune disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease(copd), malignancy, hemoglobinopathy, retinal disease, or patients who are immunosuppressed * evidence of hepatocellular carcinoma

Keywords: hepatitis hepatitis b hepatitis b virus hbv gs-9620 toll-like receptor (tlr)-7 agonist
the clinical profile of uk asthma patients with raised blood eosinophils

Conditions: Asthma

Summary: to explore the relationship between blood eosinophil counts, asthma exacerbations and patient asthma control using a large primary care based research database

sputum eosinophil levels have been shown to predict asthma exacerbation and inhaled corticosteroid (ics) responsivenesss. managing asthma based on sputum eosinophils leads to fewer exacerbations than management adhering to global initiative for asthma (gina) guidelines. however the use of sputum to measure eosinophil levels is expensive and impractical within a clinical setting. this study explores the use of blood-eosinophil levels as a clinical predictor for exacerbations and asthma control within a uk primary care dataset.

Eligibility criteria:
inclusion criteria: * patient aged 12-80 at date of last eosinophil count * asthma diagnosis at any time * blood eosinophil reading in patient record (numeric count expressed in µl) at least one year prior to last data extraction * two years of continuous data exclusion criteria: * any other chronic respiratory diseases * eosinophil counts \>5000/µl (outliers)

Keywords: asthma blood eosinophils sputum eosinophils clinical predictor uk primary care global initiative for asthma (gina)
reliability of the samsung galaxy for the detection of moderate to severe obstructive sleep apnea

Conditions: Obstructive Sleep Apnea of Adult

Summary: the study will test the reliability of the samsung galaxy for the detection of moderate to severe obstructive sleep apnea (osa)

a prospective cohort of 150 individuals 22 years or older with a prior diagnosis or with a high likelihood of having moderate to severe osa, screened using stop-bang and epworth sleepiness scale questionnaires will be recruited and will utilize the samsung galaxy watch technology to monitor sleep patterns, oxygen saturation, ppg, and heart rate variability amongst other physiologic parameters. all data will be collected over the course of two intervention nights in the sleep lab and at home for three nights.

Eligibility criteria:
inclusion criteria: * 22 years of age or older * high pre-test likelihood of moderate to severe obstructive sleep apnea (osa) based on screening questionnaires (stop-bang and epworth sleepiness scale); or prior diagnosis of moderate-severe osa. * able to provide informed consent confirmation exclusion criteria: * severe and/or other acute medical illnesses as determined by the investigator, in particular: cardiac conditions such as congestive heart failure (chf), atrial fibrillation, hx of movement disorders: parkinson's, tremor, lung conditions: chronic obstructive pulmonary disease (copd), chronic bronchitis, emphysema, pulmonary fibrosis, acute episode of flu, allergies, asthma. * active comorbid sleep disorders, such as severe insomnia, restless legs syndrome, periodic leg movement during sleep (plms), narcolepsy, idiopathic hypersomnia * severe and/or unstable psychiatric disorders such as mood, anxiety, or psychotic disorders * individual has a condition the investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk * inability to use a samsung galaxy device for sleep tracking * inability to have two nights in the stanford sleep lab. * participants who are pregnant * tattoos or scars covering the forearm area of both hands
antibiotic prophylaxis in total knee prosthesis

Conditions: Infection

Summary: knee prosthesis infection is a severe complication. the use of a tourniquet during surgery impairs the efficacy of the antibiotic prophylaxis. we hypothesize that the antibiotic administration before tourniquet release decrease the infection rate. methods: patients who undergo a total knee arthroplasty will be randomized to receive one of the following regimens of antibiotic prophylaxis:standard: cefuroxime 1.5 g i.v. 10 min before tourniquet + placebo 10 min before tourniquet release + cefuroxime 1'5 g i.v. 6h after closing surgical wound.experimental: cefuroxime 1.5 g i.v. 10 min before tourniquet + cefuroxime 1.5 g i.v. 10 min before tourniquet release + cefuroxime 1'5 g i.v. 6h after closing surgical wound.

objective: when surgery is performed under ischemia, the ideal timing for the administration of antibiotic prophylaxis has not been well defined. currently, antibiotics are given 10 minutes before ischemia and the infection rate is about 3-5%. in 2005 we performed a study where the efficacy of the standard prophylaxis was compared with a new regimen that consisted in administering the antibiotic 10 min. before tourniquet release. the results were positive although the difference was not statistically significant. in the present study we are proposing a new protocol where the antibiotic is given 10 min. before the inflation of tourniquet and 10 min. before its release. methodology: all patients who undergo a total knee arthroplasty will be randomized to receive one of the following regimens of antibiotic prophylaxis:standard: cefuroxime 1.5 g i.v. 10 min before tourniquet + placebo 10 min before tourniquet release + cefuroxime 1'5 g i.v. 6h after closing surgical wound.experimental: cefuroxime 1.5 g i.v. 10 min before tourniquet + cefuroxime 1.5 g i.v. 10 min before tourniquet release + cefuroxime 1'5 g i.v. 6h after closing surgical wound.the infection rate with standard regimen is 3.4%. we believe that the new regimen will decrease the rate of infection to 1%. to demonstrate differences between both arms, it will be necessary to include 666 patients per arm.

Eligibility criteria:
inclusion criteria: * patients undergoing knee arthroplasty exclusion criteria: * patients allergic to penicillin

Keywords: infection after total knee arthroplasty
remission through early monitored insulin therapy - duration month

Conditions: Type 2 Diabetes Mellitus

Summary: remit-dm is a feasibility pilot study where participants will be recruited soon after their diagnosis of type 2 diabetes to be placed immediately on insulin therapy for maximum of four weeks with titrations of insulin guided by glucose levels and trends provided by a continuous glucose monitor (cgm), with the purpose of achieving diabetes remission.

remit-dm is a feasibility pilot study that aims to show that previously published diabetes remission through early use and titration of short-term insulin therapy is possible and safe in the ambulatory diverse american population of patients with t2d, with continuous glucose level and trend information provided by cgm. we developed the algorithm based on published diabetes remission studies and include within the algorithm the cgm trend arrows to further refine insulin doses for both safety and efficacy purposes. data captured by the cgm transmits automatically to the cloud and is accessible at any time of day by the multidisciplinary diabetes team, which includes the certified diabetes educator (cde) and endocrinologist. the cgm-guided insulin titration algorithm is designed to achieve euglycemia (defined as fasting cbg \< 100 mg/dl, and 2 hour post-prandial cbg \< 120 mg/dl) within 2 weeks of initiating insulin therapy, then to help maintain euglycemia for 2 weeks before discontinuing insulin entirely. ten participants will undergo a maximum of 4 weeks of insulin therapy and will be assessed for remission afterwards to confirm enough recovery of beta cell function. (complete remission is defined as fasting glycemia \<100 mg/dl without use of pharmacological therapy.) afterwards, we will implement american diabetes association (ada) guidelines for standard glycemic management, as necessary. we will use the data collected during this feasibility study to sharpen the cgm-guided insulin titration algorithm for creation of a t2dm remission mobile application that could then be tested and studied in a larger sample size. the feasibility study will also take into account clinically meaningful data points e.g. the number of phone calls between the patient and the diabetes team, the patient experience, and patient satisfaction.

Eligibility criteria:
inclusion criteria: 1. age ≥18 2. a1c criteria - \>7.0 3. newly diagnosed with t2d within 4 years 4. lifestyle controlled 5. subject may be on up to 2 medications for diabetes. 6. smart phone or home computer compatible with dexcom clarity software 7. english speaking 8. assessed by endocrinologist and diabetes educator to be able to perform skills necessary for cgm use and insulin delivery exclusion criteria: 1. autoimmune type 1 dm, defined as positive gad65 or islet cell antibodies 2. pregnant 3. chronic kidney disease (ckd) stage iv or greater 4. mental and/or cognitive disorder (based on documented disorder and/or assessment of physician or educator) 5. no access to computer for downloading cgm 6. bmi \<18.0

Keywords: insulin therapy continuous glucose monitor
parental well-being after childbirth in switzerland

Conditions: Mental Health; Physical Health; Postpartum; Parents; Quality of Life; Quality of Care; Stress Disorder, Post Traumatic

Summary: improving maternal and child health is a global priority, with increasing emphasis on ensuring women and their families not only survive but also thrive after childbirth. while high-income countries like switzerland provide strong antenatal and intrapartum care, the quality of postnatal care often lags behind, despite the critical physical, mental, and social needs of the postpartum period. studies indicate high rates of mental distress, physical pain, and sexual discomfort among mothers, alongside a lack of research on the well-being of co-parents. the main question this cohort study aims to answer is: how do the health and well-being of mothers and co-parents evolve during the first year after childbirth? participants will complete four online questionnaires: the first within the first few days after birth, followed by additional assessments at 2, 6, and 12 months postpartum. this comprehensive approach seeks to inform policy and improve evidence-based postnatal care practices, benefiting approximately 80,000 families annually in switzerland.


Eligibility criteria:
inclusion criteria: * women who give birth in a participating maternity unit or birth center during the study period. * partner of a participating women: the partner must be designated by the mother, live with her at the time of birth, and only one partner can be included per mother. * gestational age at birth: ≥22+0 weeks and/or birthweight ≥500 grams * age: participants must be 14 years or older. * language proficiency: participants must have sufficient proficiency in one of switzerland's main official languages (german, french, italian) or english to ensure accurate communication and comprehension of study materials. exclusion criteria: * refusal to participate * inability to provide informed consent

Keywords: childbirth-related post-traumatic stress disorder mental health postpartum parental wellbeing physical health sexual health social support quality of life quality of care postpartum depression mothers coparents
hypoalgesic effect of electrical current and cervical manipulation

Conditions: Pain

Summary: this study evaluates the hypoalgesic effect of the tens application associated with joint manipulation of the cervical region in healthy individuals. one group had both active treatments, the other group received both placebo treatments, the third and fourth group received only one of the two treatments actively and the other placebo

transcutaneous electrical nerve stimulation (tens) and cervical joint manipulation (cjm) are often used for pain treatment. tens also promotes analgesia by activating a descending pathway, which originates in the periaqueductal grey (pag) and in the rostroventromedial medulla (rvm) to inhibit the excitability of nociceptive neurons in the dorsal horn of the spinal cord. joint manipulation generates a series of stimuli within the central nervous system through the activation of proprioceptors located in the joint capsule or muscles, stimulates the pag, causing pain inhibition by activation of non-opioid descending inhibitory pathways

Eligibility criteria:
inclusion criteria: * healthy subjects * no pain complaints from the last 90 days exclusion criteria: * previous spinal surgeries * spinal canal stenosis * vertebral fracture * spondylolisthesis * cancer * acute infections * hemorrhagic disorders * active tuberculosis * deep vein thrombosis * osteoporosis * diseases rheumatic * diseases metabolic * cardiorespiratory diseases * headache in the last seven days * smoking * changes in skin sensitivity * use of pacemaker * women in menstrual period * pregnant women * use of pain-killers in the last 48 hours * use of anti-inflammatory drugs in the last 48 hours * previous electrostimulation * previous cervical joint manipulation treatments * hypersensitivity to tens application * aversion to cervical joint manipulation * positive test for vertebral artery.

Keywords: tens cervical manipulation pressure pain
dose escalation study for primary hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of this study is to determine the maximum tolerated dose of limited fractions of large dose radiation in an effort to achieve a biologically potent cancer therapy in selected patients with primary hepatocellular carcinoma.

despite recent advances in early detection and diagnosis, only 30-40% of patients with hepatocellular carcinoma may benefit from radical therapies. liver transplantation offers the best chance for cure. surgical resection has been the only other potentially curative option, but the majority of patients are not candidates for resection. this reflects the usual comorbidity of severe underlying liver disease that either precludes surgery or makes the surgical approach extremely dangerous.

Eligibility criteria:
inclusion criteria: evaluation by the surgery and/or liver transplant team has been performed and the patient is not considered a candidate for either "standard" therapy to target area (upper abdomen) * adequate liver function defined as: * total bilirubin \ 2.5 g/dl * normal pt/ptt unless on anticoagulants * mild elevation of liver enzymes acceptable (must be less than three times upper limit of normal) * adequate renal function (creatinine \< 1.8 mg/dl or creatinine clearance ≥ 50 ml/min) * adequate bone marrow reserve: * anc count ≥ 1500 mm3 * platelets ≥ 50,000/mm3 * hemoglobin \> 9 g/dl note: lab values must be obtained within 2 weeks prior to being registered for protocol therapy. exclusion criteria: * no history of systemic lupus erythematous, rheumatoid arthritis, systemic sclerosis or scleroderma * no chemotherapy within 14 days before radiotherapy (chemotherapy may cause transient hepatitis with hepatomegaly) * no subsequent chemotherapy planned within 2 weeks of radiotherapy * no active liver infection * no acute hepatitis. definition of active disease: * hepatitis a: acute hepatitis determined by presence of anti-hav- igm * hepatitis b: 1. hbsag (hb surface antigen): present in patients with acute and chronic hepatitis 2. hbv dna present in patients with active viral replication in amounts greater than 100,000 copies 3. hbeag is present in wild type hbv infection and suggests active replication 4. anti-hbs: antibody against hbsag appears after hbv infections and confers immunity 5. anti-hbc-igm: antibody against hbcag, fraction igm, present in acute infection and often could be detected during periods of high viral replication in chronic disease 6. anti-hbc-igg: is present in chronic disease
cardio- and renoprotective effect of remote ischemic preconditioning in patients undergoing percutaneous coronary intervention

Conditions: Coronary Artery Disease

Summary: myocyte necrosis occurs frequently in elective percutanious percutaneous coronary intervention (pci) and is associated with subsequent cardiovascular events. this study assessed the cardio- and reno-protective effect of remote ischemic preconditioning (ripc) in patients undergoing elective pci. 200 patients were randomized into 2 groups: 100 patients received ripc (created by three 5-minute inflations of a blood pressure cuff to 200 mm hg around the upper arm, separated by 5-minute intervals of reperfusion) \< 2 hours before the pci procedure, and the control group (n = 100).


Eligibility criteria:
inclusion criteria: * patients between 18 and 85 years of age, * scheduled to undergo an elective pci and * able to give an informed consent were eligible for enrollment in the study. * elective pci was defined as any coronary revascularization in a low-risk patient who presents to the facility for a planned pci or for a coronary angiogram followed by ad hoc pci. exclusion criteria: * (1) emergency pci, (2) baseline troponin value ≥ 0.04 ng/ml, (3) nicorandil or glibenclamide use (preconditioning-mimetic and preconditioning-blocking medication, respectively), (4) those who could not give informed consent, and (5) patients with severe renal impairment or on regular dialysis.

Keywords: remote ischemic preconditioning